vs
Side-by-side financial comparison of FOX FACTORY HOLDING CORP (FOXF) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $361.1M, roughly 1.7× FOX FACTORY HOLDING CORP). On growth, FOX FACTORY HOLDING CORP posted the faster year-over-year revenue change (2.3% vs -10.5%). Over the past eight quarters, FOX FACTORY HOLDING CORP's revenue compounded faster (1.8% CAGR vs -6.6%).
Fox Factory Holding Corp. is an American company best known for their Fox Racing Shox brand of off-road racing suspension components.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
FOXF vs QDEL — Head-to-Head
Income Statement — Q4 FY2027 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $361.1M | $619.8M |
| Net Profit | — | $-91.8M |
| Gross Margin | 28.3% | — |
| Operating Margin | -13.0% | — |
| Net Margin | — | -14.8% |
| Revenue YoY | 2.3% | -10.5% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-6.86 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 26 | $361.1M | — | ||
| Q1 26 | $368.7M | $619.8M | ||
| Q4 25 | $376.4M | — | ||
| Q3 25 | $374.9M | $699.9M | ||
| Q2 25 | $355.0M | $613.9M | ||
| Q1 25 | $352.8M | $692.8M | ||
| Q4 24 | — | $707.8M | ||
| Q3 24 | $359.1M | $727.1M |
| Q4 26 | — | — | ||
| Q1 26 | $-15.0M | $-91.8M | ||
| Q4 25 | $-634.0K | — | ||
| Q3 25 | $2.7M | $-733.0M | ||
| Q2 25 | $-259.7M | $-255.4M | ||
| Q1 25 | $-141.0K | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | $4.8M | $-19.9M |
| Q4 26 | 28.3% | — | ||
| Q1 26 | 28.9% | — | ||
| Q4 25 | 30.4% | — | ||
| Q3 25 | 31.2% | — | ||
| Q2 25 | 30.9% | — | ||
| Q1 25 | 28.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 29.9% | — |
| Q4 26 | -13.0% | — | ||
| Q1 26 | 72.8% | — | ||
| Q4 25 | 4.0% | — | ||
| Q3 25 | 4.9% | -100.7% | ||
| Q2 25 | -70.6% | -29.4% | ||
| Q1 25 | 3.2% | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | 5.2% | 2.1% |
| Q4 26 | — | — | ||
| Q1 26 | -4.1% | -14.8% | ||
| Q4 25 | -0.2% | — | ||
| Q3 25 | 0.7% | -104.7% | ||
| Q2 25 | -73.1% | -41.6% | ||
| Q1 25 | -0.0% | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | 1.3% | -2.7% |
| Q4 26 | $-6.86 | — | ||
| Q1 26 | $-0.36 | $-1.35 | ||
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $0.07 | $-10.78 | ||
| Q2 25 | $-6.23 | $-3.77 | ||
| Q1 25 | $0.00 | $-0.19 | ||
| Q4 24 | — | $-2.54 | ||
| Q3 24 | $0.11 | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.0M | $140.4M |
| Total DebtLower is stronger | $26.9M | $2.5B |
| Stockholders' EquityBook value | $670.2M | $1.9B |
| Total Assets | $1.7B | $5.6B |
| Debt / EquityLower = less leverage | 0.04× | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q4 26 | $58.0M | — | ||
| Q1 26 | $53.9M | $140.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | $71.7M | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | — | $143.7M |
| Q4 26 | $26.9M | — | ||
| Q1 26 | $26.9M | $2.5B | ||
| Q4 25 | $536.7M | — | ||
| Q3 25 | $541.8M | $2.5B | ||
| Q2 25 | $546.9M | $2.1B | ||
| Q1 25 | $552.1M | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | $558.4M | $2.2B |
| Q4 26 | $670.2M | — | ||
| Q1 26 | $658.8M | $1.9B | ||
| Q4 25 | $956.0M | — | ||
| Q3 25 | $958.7M | $2.0B | ||
| Q2 25 | $939.9M | $2.8B | ||
| Q1 25 | $1.2B | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | $1.2B | $3.2B |
| Q4 26 | $1.7B | — | ||
| Q1 26 | $1.7B | $5.6B | ||
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | $5.7B | ||
| Q2 25 | $1.9B | $6.4B | ||
| Q1 25 | $2.2B | $6.5B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | $2.3B | $6.8B |
| Q4 26 | 0.04× | — | ||
| Q1 26 | 0.04× | 1.33× | ||
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.57× | 1.23× | ||
| Q2 25 | 0.58× | 0.74× | ||
| Q1 25 | 0.46× | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | 0.47× | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 26 | $60.9M | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $5.3M | — | ||
| Q3 25 | $36.8M | $-45.5M | ||
| Q2 25 | $680.0K | $-46.8M | ||
| Q1 25 | $81.7M | $65.6M | ||
| Q4 24 | — | $63.7M | ||
| Q3 24 | $14.1M | $117.9M |
| Q4 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-2.5M | — | ||
| Q3 25 | $24.6M | $-94.7M | ||
| Q2 25 | $-6.5M | $-84.3M | ||
| Q1 25 | $69.8M | $9.4M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | $3.2M | $71.4M |
| Q4 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -0.7% | — | ||
| Q3 25 | 6.6% | -13.5% | ||
| Q2 25 | -1.8% | -13.7% | ||
| Q1 25 | 19.8% | 1.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 0.9% | 9.8% |
| Q4 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | — | ||
| Q3 25 | 3.3% | 7.0% | ||
| Q2 25 | 2.0% | 6.1% | ||
| Q1 25 | 3.4% | 8.1% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | 3.0% | 6.4% |
| Q4 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 13.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOXF
| Aftermarket Applications Group | $126.2M | 35% |
| Specialty Sports Group | $118.2M | 33% |
| Powered Vehicles Group | $116.7M | 32% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
